Delving into the Latest Updates on Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEye Diseases+ [1]

Active Indication

BlindnessRetinitis Pigmentosa

Inactive Indication

Acute myocardial infarctionCerebral PalsyInfarction+ [2]

Originator Organization

PT Prodia Stemcell Indonesia

Active Organization

PT Prodia Stemcell Indonesia

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.

Start Date01 Aug 2025

Sponsor / Collaborator

PT Prodia Stemcell Indonesia

NCT05786287

/ Enrolling by invitationNot Applicable

Long-term Safety of Umbilical Cord-Mesenchymal Stem Cell (UC-MSC) Transplantation in Patients With Retinitis Pigmentosa

The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.

Start Date01 Jul 2023

Sponsor / Collaborator

PT Prodia Stemcell Indonesia

NCT05935423

/ Unknown statusPhase 3IIT

Intracoronary Allogenic Umbilical Cord Mesenchymal Stem Cell Reduce Infarct Size, Reverse Remodelling, and Improve Cardiac Function

The goal of this clinical trial is to learn about the effectiveness of Umbilical Cord Mesenchymal Stem Cell (UC MSC) therapy in patients with STEMI against infarct myocardial size reduction and prevent the incidence of heart failure in the future

Start Date01 Jul 2023

Sponsor / Collaborator

University of Indonesia

[+1]

100 Clinical Results associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)

Login to view more data

100 Translational Medicine associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)

Login to view more data

100 Patents (Medical) associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)

Login to view more data

100 Deals associated with Umbilical Cord MSCs therapy(PT. Prodia Stem Cell Indonesia)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Blindness	Phase 3	Indonesia	PT Prodia Stemcell Indonesia	01 Aug 2025
Retinitis Pigmentosa	Phase 3	Indonesia	PT Prodia Stemcell Indonesia	01 Aug 2025
Infarction	Phase 3	Indonesia	PT Prodia Stemcell Indonesia	01 Jul 2023
ST Elevation Myocardial Infarction	Phase 3	Indonesia	PT Prodia Stemcell Indonesia	01 Jul 2023
Ischemic stroke	Phase 2	Indonesia	PT Prodia Stemcell Indonesia	30 May 2022
Cerebral Palsy	Phase 2	Indonesia	PT Prodia Stemcell Indonesia	13 Oct 2021
Acute myocardial infarction	Phase 2	Indonesia	PT Prodia Stemcell Indonesia	11 Mar 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02481440 (CTgov)	Phase 1/2	Spinal Cord Injuries	102	human umbilical cord mesenchymal stem cells	xmjntesloa(duizpemben) = teihlgfiox uhiospjdmg (qplcyjovps, 69.76) View more	-	30 Jun 2020